Introduction: Rituximab plus fludarabine and cyclophosphamide (RFC) is the standard of care for fit patients with untreated chronic lymphocytic leukemia (CLL); however, its use is limited in 'unfit' (co-morbid and/or full-dose F-ineligible) patients due to its toxicity profile. We conducted a systematic review and Bayesian network meta-analysis (NMA) to determine the relative efficacy of commercially available interventions for the first-line treatment of unfit CLL patients.
had to be linked via common treatment comparators, report progression-free survival (PFS), and/or overall survival (OS), and meet at least one of the five inclusion criteria: median cumulative illness score [6, median creatinine clearance B70 mL/min, existing co-morbidities, median age C70 years, and no full-dose F in the comparator arm. A manual review, validated by external experts, of all studies that met at least one of these criteria was also performed to confirm that they evaluated first-line therapeutic options for unfit patients with CLL. 
Results

INTRODUCTION
Rituximab in combination with fludarabine and cyclophosphamide (RFC) is currently the standard of care for medically fit patients with previously untreated chronic lymphocytic leukemia (CLL) [1] [2] [3] . However, many patients with CLL are in their 70's and beyond before they need to start treatment, and are likely to have a greater co-morbidity burden [4] . For this often medically unfit population, RFC is unsuitable, with data from several clinical studies suggesting that the regimen is associated with excessive toxicity (e.g., cytopenias and increased infection rates)
relative to the remission rates achieved [5, 6] .
Other therapeutic options are available for unfit patients with CLL and include chlorambucil (Clb) in combination with an anti-CD20 antibody such as rituximab (R-Clb), obinutuzumab (G-Clb) or ofatumumab (O-Clb), rituximab in combination with bendamustine (R-Benda), dose-reduced fludarabine with cyclophosphamide (FC), and a dose-modified RFC regimen (RFC-Lite) [2] [3] [4] [7] [8] [9] [10] 0.339-0.806; P = 0.003) [10] , and with G-Clb compared with the equivalent rituximab regimen in the CLL11 study (29.2 versus 15.4 months; HR 0.40; 95% CI 0.33-0.50; P\0.001) [11] ; however, with a limited number of head-to-head treatment comparisons available, the optimal treatment for unfit patients with CLL remains unclear.
Network meta-analysis (NMA) allows information from direct head-to-head studies to be combined with information from indirect treatment comparisons to enable estimation of the comparative efficacy of therapies and build a hierarchy of available treatments [12, 13] .
Furthermore, the outputs of NMA-based comparative effectiveness research can be used in a full economic appraisal of competing interventions to assess the cost-effectiveness [14] . The usefulness of NMA has been demonstrated across a range of therapeutic interventions and disease areas including CLL [15] [16] [17] [18] [19] [20] . Naïve comparison of drug treatments based on data from different studies carries with it a risk of making incorrect conclusions; by assuming the constancy of relative treatment effects (odds ratios or HRs) to link studies, NMA minimizes this risk. We, therefore, conducted a systematic review and Bayesian NMA of data from all RCTs comparing at least two interventional treatments in patients presenting with 'first-line' CLL and/or who were not eligible to receive full-dose fludarabine (F) to determine the relative effects of treatments on PFS and overall survival (OS).
METHODS
Data Source and Searches
We conducted an initial literature search plus two updates of five databases (Embase Ò , 
Study Selection
The systematic literature search and screening process for trials are described in section B of the supplementary material. Two independent reviewers screened the titles and abstracts of all identified studies to produce a list of potentially relevant studies. They then performed a detailed screening of the full-text versions of these studies to identify the final list of studies for consideration in the analysis.
When reviewing the full text, the objective was to identify whether the study inclusion criteria allowed for the enrollment of patients with co-morbidities, such as renal impairment. In addition, during the same full-text review, the baseline characteristics of patients included in the studies were reviewed to identify (if any) the level of co-morbidities. Any discrepancies in the decisions of the two reviewers were resolved by a third independent reviewer.
Studies selected for inclusion in the NMA were RCTs comparing first-line treatment in patients with CLL. Also, included studies had to be linked via common treatment comparators, to report PFS and/or OS data, and were required to meet at least one of five 'co-morbidity' inclusion criteria in descending sequence priority: a median cumulative illness rating score (CIRS) of [6, median creatinine clearance B70 mL/min, existing co-morbidities (particularly relating to renal impairment), median age C70 years, and/or no full-dose F in the comparator arm. These five criteria served as the basis for the identification of publications in the literature that may have evaluated first-line treatments for co-morbid/unfit patients with CLL. A final manual review of all the studies that met at least one of these five criteria was performed and then validated by external experts in the field of CLL, to confirm whether the identified studies did, in fact, evaluate the first-line therapeutic options for co-morbid/unfit and/or full-dose F-ineligible patients with CLL.
Data Extraction and Statistical Analysis
For each selected trial, unadjusted HRs for PFS and OS were extracted into a pre-defined extraction grid to ensure that the data were extracted uniformly and were comparable across studies. Data were independently extracted by two analysts, with their results checked and reconciled by a third-party independent analyst. If HR data were not reported, HRs were estimated using a method that was appropriate for the available published PFS/OS statistic. For example, if the median PFS/ OS was reported, an exponential distribution was assumed and the HR was estimated as the ratio of the median PFS/OS time for the two treatment arms [21] . In papers where landmark PFS/OS data were reported (e.g., 3-year PFS), proportionality of hazard functions was assumed and the HR was calculated as HR = lnS 1 (t)/lnS 0 (t), where S 0 (t) and S 1 (t) denote survival estimates at time t for the control and treatment arm, respectively. In only two of the trials, HRs were not reported and were estimated.
NMA as presented in this manuscript was based on the natural logarithms of the HRs (lnHR) and standard deviations (SDs). Published CIs or log-rank P values (in two cases where HRs values were not reported) were used to estimate SDs for lnHRs [22] .
Network Meta-Analysis
The NMA was conducted using a hierarchical, contrast-based model where lnHR i of trial i follows a normal distribution centered at the (unknown) treatment effect with an SD equal to SD i . To deal with three-arm trials, we followed the approach described by Dias et al. [23] . Fixed effects (FE) and random effects (RE) models were explored. The latter accounted for between-study variation using a heterogeneity parameter s.
The NMA was performed for PFS and OS on two different evidence networks: the main analysis was based on a network of five studies for PFS and four studies for OS, which were selected according to the five pre-defined criteria and expert opinion (base-case analysis);
an additional analysis was also conducted based on a secondary evidence network that included an additional three studies (i.e., a total of eight studies for PFS and seven studies for OS that met . This prior has its mode at 0 and is steadily declining in s, with an upper 95% point at s u .
We set s u at 0.25, which yields an informative prior (a heterogeneity parameter of s u = 0.25 translates to HRs ranging from 0.61 to 1.63
[26]). We note that uninformative priors on s are not appropriate in this setting as most comparisons are informed by a single study (see ''Results'').
All results were reported as median posterior
HRs with corresponding 95% credible intervals (CrIs). The treatments were ranked in each MCMC simulation, and medians and 95% CrIs of the posterior ranks were reported. Further, posterior probabilities of being the best treatment were obtained as the proportion of simulations in which each treatment had the smallest HR.
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. Following screening and examination of the papers, we selected a total of eight RCTs that met at least one of the five pre-defined criteria: CLL11, CLL5, COMPLEMENT 1, Nikitin, MaBLe, Knauf, CAM307, and CALGB9011 [8] [9] [10] [27] [28] [29] [30] [31] . According to expert feedback, three of the studies, Knauf, CAM307, and CALGB9011, did not match the typical unfit patient scenario and were considered to have included patients who were more fit compared with the other RCTs. Table 1 Table 2 . 
RESULTS
Systematic Review and Included Studies
Network Meta-Analysis
Additional Analysis
The analysis was repeated on all eight trials identified using the five F-ineligibility criteria (no expert assessment). Inclusion of an additional three studies made minimal difference to the estimated treatment effects and the rank ordering of treatments ( Fig. 3 ; Table 4 ). These findings for the additional analysis were consistent for both the FE and RE models. Data for the additional analysis using the RE model are summarized in the supplementary material, sections D and E.
For OS, of note was the narrower CrI for the comparison of G-Clb versus F (FE model: HR 0.57, CrI 0.34, 0.95) compared with the wide CrI presented earlier in the main analysis. The higher precision in the additional analysis is a consequence of the combined evidence from the CLL5 and CALGB9011 trials. chlorambucil (G-Clb) is likely to be superior to many other treatment options including Benda, R-Clb, O-Clb, Alm, F, and Clb in unfit patients with CLL. In addition, G-Clb showed a trend for greater efficacy over the regimens RFC-Lite and R-Benda in this setting. Our results for OS were generally consistent with the data on PFS, suggesting beneficial outcomes with G-Clb over other regimens, and were driven by the consistent trend in OS favoring G-Clb in the CLL-11 trial [11, 27, 32] . However, the OS data in our study were associated with greater uncertainty, and this was not unexpected given that the follow-up times for OS were relatively short. We also note that to the best of our knowledge, PFS has not yet been validated as a surrogate endpoint for OS in the first-line treatment of unfit patients with CLL within a meta-analytic framework [33] .
Our NMA of PFS (additional analysis) also supported the findings of the Knauf study suggesting that Benda is a more potent chemotherapy, leading to 'deeper' remission than the traditional agent Clb in unfit patients [29] . Given this finding, it was of interest to note a trend favoring the combination of obinutuzumab with Clb over rituximab combined with Benda, as shown by the HR estimate for PFS (0.81 CrI 0.49, 1.33).
Through the use of pre-defined 'co-morbidity' inclusion criteria combined with expert review, we were able to restrict our analysis to unfit patients with CLL who were likely to meet the unfit definition as described in the CLL11 trial unlikely that the patients included were not eligible for full-dose F) [29] . It is also important to note that the three excluded studies were conducted at a time when Clb (rather than RFC) was the standard of care even in fit patients, since at that time, no treatment had shown an OS benefit over Clb. Also, these studies were not designed to explicitly enroll unfit patients, their median age was substantially lower than the remaining five studies, and chemotherapy alone is not currently considered a relevant treatment option (even in unfit CLL).
An important advantage of NMA over naïve inter-trial comparisons is that the calculations are based on relative treatment effects (in terms of HRs) rather than absolute effects. Thereby, NMA circumvents the potential incomparability of two studies due to differences in the distributions of measured and/or unmeasured prognostic factors. For example, a naïve comparison of the R-Benda arm in MaBLe (median PFS 39.6 months) [10] with the G-Clb arm in CLL11 (median PFS 29.2 months) [11] would have led to the opposite conclusion of better performance of R-Benda versus G-Clb. This naïve comparison compares efficacy on an 'absolute' scale and ignores the fact that the common comparator R-Clb in these two studies showed substantial discrepancy in terms of median PFS (29.9 months in MaBLe and 15.4 months in the CLL11 study, respectively). The prognostic differences that lead to this study bias between MaBLe and CLL11 may be manifold with differences in methodology of data generation and data read-out as the main drivers. We note that our NMA does not account for potential effect modifiers, which are defined as patient or study characteristics that influence the two treatment arms to a different extent and, The results of our NMA should ideally be validated in independent studies, and our findings should be interpreted taking into account a number of limitations. First, a limited number of studies were eligible for inclusion in the analysis. Many of the comparisons were informed by a single trial (e.g., CLL11 was the only trial to compare G-Clb and R-Clb). This limited the statistical assessment of heterogeneity and inconsistency and also precluded the performance of more sophisticated analyses, for example, meta-regression to adjust for potential effect modifiers. Our selection strategy (five criteria and expert opinion) also aimed at increasing the homogeneity of the trials in the network.
Nonetheless, the levels of unfitness still varied among the selected trials, which could ultimately have influenced our NMA. Second, the follow-up times for OS (and to a lesser extent PFS) were relatively short; longer follow-up would likely have impacted on the effect size, especially the CrIs. Third, in two trials, assumptions were required to calculate lnHR and SD, and these estimates may have differed from the estimate of HR using whole Kaplan-Meier curves.
Our results are comparable with the findings reported by Ladyzynski et al. [16] 
CONCLUSIONS
Results from our NMA demonstrate a clear preference in terms of PFS for G-Clb versus R-Clb, O-Clb, fludarabine and chlorambucil, and a trend for better efficacy versus R-Benda and RFC-Lite. A higher degree of uncertainty was associated with the OS results, but the findings were generally consistent with PFS data. Together, these data support the conclusion that G-Clb is an effective first-line treatment for unfit patients with CLL and is likely to show superior efficacy compared with other treatment options. 
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